CEL-SCI Corp

View in Terminal

Loading quotes...

Forecast

Buy	6
Hold	0
Sell	0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics

In 1996, CEL-SCI Corp has already paid €1,499.10 in dividends. The last payout was in September 1996.

Financials

In the last quarter, CEL-SCI Corp had revenue of €0 and net profit of -€4.97m

(EUR)	June 2026	YoY
Revenue	0	-
Gross profit	-829.22k	1.91%
Net profit	-4.97m	3.33%
EBITDA	-4.04m	5.04%

Fundamentals

Metric	Value
Market capitalization	€20.84m
Number of shares	17.59m
52-week high/low	€7.05 - €0.80
Dividends	No
Beta	0.62
P/E ratio	-0.51
PEG ratio	0.00
P/B ratio	1.45
P/S ratio	0.00

Company profile

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.